Previous 10 | Next 10 |
There is a lot of uncertainty in the market that the number of Coronavirus cases will keep increasing exponentially. This could cost tens of thousands of peoples' lives and would impact the worldwide economy, which was already poor . Although the real consequences are still unclear, it will c...
Galapagos Receives Rating Downgrade, Stock Skids Galapagos NV ( GLPG ) stock was hit hard as Bank of America downgraded its rating to Sell. The latest downgrade comes after a couple of other such negative recommendations made by other stock research firms. The pharma company stock was rece...
The ability of Gilead Sciences ( GILD ) to make a run at new highs must speak to bullishness surrounding the coronavirus because the biopharma is struggling to complete the expected turnaround. In addition, new management made the unwise decision to remove stock-based compensation from non...
Galapagos (NASDAQ: GLPG) galloped to all-time highs heading into this week. Although a pullback in the overall market has caused the biotech to give up some of its gains, Galapagos is still up close to 20% year to date and up around 150% over the past 12 months. Some investors could vi...
Galapagos ( GLPG -10.1% ) goes south after BofA Merrill Lynch downgrades shares to Underperform from Neutral with a $213 price target, citing the stock's valuation and risk-reward profile. More news on: Galapagos NV, Healthcare stocks news, Stocks on the move, Read more ...
Gilead Sciences (NASDAQ: GILD) has been getting a lot of attention these days for remdesivir, its possible treatment for the coronavirus, which so far has resulted in more than 2,000 deaths. Even though remdesivir could be a plus for the company if approved, there are still too many unknowns...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q4 2019 Earnings Call Feb 21, 2020 , 8:00 a.m. ET Operator Continue reading
Galapagos NV (GLPG) Q4 2019 Earnings Conference Call February 21, 2020 08:00 AM ET Company Participants Elizabeth Goodwin - Vice President, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid ...
The following slide deck was published by Galapagos NV in conjunction with their 2019 Q4 earnings Read more ...
Galapagos ( GLPG ) FY2019 results ((€)): More news on: Galapagos NV, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...